Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab). This version, which will be marketed ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...
Mosunetuzumab's subcutaneous formulation offers a 1-minute injection, improving convenience over the previous intravenous infusion for relapsed or refractory follicular lymphoma. The phase 1/2 GO29781 ...
A year after an FDA rejection, Johnson & Johnson has won approval for a more convenient version of its lung cancer drug Rybrevant to better challenge AstraZeneca’s Tagrisso. Rybrevant Faspro, a ...
Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...
The first trials of glucagon-like peptide-1 (GLP-1) receptor agonists in adolescents diagnosed with overweight and obesity are underway in Russia, according to the press service of the St.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback